Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Genmab's HuMax-CD4 to Treat Lymphoma Awarded Fast Track Status from FDA23 Mar 2004
Genmab, Amgen Announces Positive HuMax-IL15 Interim Phase II Data23 Mar 2004
Genmab, quarterly statement of shareholdings22 Mar 2004
Genmab, Roche Selects Two Genmab Antibodies as Clinical Candidates19 Mar 2004
Genmab, current statement of shareholdings19 Mar 2004
Genmab, current statement of shareholdings17 Mar 2004
Genmab, annual report 200316 Mar 2004
Genmab, current statement of shareholdings
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
16 Mar 2004
Genmab, notice convening annual general meeting the 1. April 200410 Mar 2004
Genmab, Capital Increase as a Result of Employees' Warrant Exercise9 Mar 2004
Genmab, current statement of shareholdings9 Mar 2004
Genmab, articles of association from the March 9, 20049 Mar 2004
  • Previous
  • 1
  • More pages
  • 143
  • 144
  • 145
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863